RecruitingNCT04085029
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Sponsor
Duke University
Enrollment
300 participants
Start Date
Sep 26, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years of age
- Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
- Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
- Patient must sign study-specific informed consent
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04085029
Related Trials
Evaluating Disparities in Precision Oncology
NCT060815171 location
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047126 locations
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT056862263 locations
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT0542291112 locations
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT050767602 locations